Tradestie Institutional Equity Comparison Engine

STOK vs NUVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

STOK Overall Edge

STOK Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Stoke Therapeutics, Inc. Common Stock (STOK) driven by superior Momentum & Technical, Options & Structure while NUVB counters with relative strength in Growth & Margin. Fundamentally, STOK trades at N/M Forward P/E with -913.2% operating margin (+5.9% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, STOK sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
STOK N/M vs NUVB N/M Fwd P/E
Growth & Margin Winner NUVB
Op Margin -913.2% vs -61.2% ยท YoY +5.9% vs +242.6%
Momentum & Technical Winner STOK
1Y -5.9% vs -46.9% ยท 52W Pos 26% vs 2%
Options & Structure Winner STOK
SURGE (8th %ile IV) vs BREAKDOWN (26th %ile IV)
STOK NASDAQ
Stoke Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$26.81
-0.45% 1D
Market Cap $1.8B
1M Return +4.32%
1Y Return -5.86%
Forward P/E N/M
Unified AI Score
55.9 / 100 HOLD
Tech 43.0 Fund 56.0 Flow 64.0 Mom 60.0
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: STOK -5.86% NUVB -46.85% Spread: +40.99 pp (STOK Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period STOK Revenue NUVB Revenue STOK Op. Margin NUVB Op. Margin Margin Edge
FY2022 $10M N/A -841.2% N/A STOK
FY2023 $10M N/A -1307.2% N/A STOK
FY2024 $40M $10M -277.3% -7527.3% STOK
FY2025 $180M $60M -11.2% -338.7% STOK

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: STOK (4) vs NUVB (4)
Institutional Metric STOK NUVB Criterion Row Winner
Market Capitalization Scale $1.8B $1.3B Larger Scale STOK
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +5.9% +242.6% Higher Growth NUVB
Operating Margin (TTM) Profitability -913.2% -61.2% Higher Margin NUVB
Net Profit Margin Profitability 0.0% -67.4% Higher Margin STOK
Return on Equity (ROE) Capital Efficiency -73.6% -49.1% Higher ROE NUVB
52-Week Range Position Momentum 26% ($22โ€“$40) 2% ($4โ€“$10) Stronger Trend STOK
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 38% Vol 1.52ฮฒ ยท 55% Vol Lower Realized Risk STOK
Unified Institutional Score Composite Signal 55.9 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full STOK vs NUVB Buy Guide
STOK SURGE
7d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live STOK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither STOK nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.